Artículos Científicos

Artículos Científicos

  1. Yang MH, et al. Possible differentiation of cerebral glioblastoma into pleomorphic xanthoastrocytoma: an unusual case in an infant. J Neurosurg Pediatrics 9: 517 – 523. (2012).
  2. Warner, S. Diagnostics + Therapy = Theranostics. Strategy requires teamwork, partnering, and tricky regulatory maneuvering. The Scientist 18 (16): 38. (2004).
  3. Dancey, J.E. et al. The Genetic Basis for Cancer Treatment Decisions. Cell 148: 409-420 (2012).
  4. Beadling C. et al. Multiplex Mutation Screening by Mass Spectrometry: Evaluation of 820 Cases from a Personalized Cancer Medicine Registry. The Journal of Molecular Diagnostics 13 (5): 504-513. (2011).
  5. Meric-Bernstam F. et al.Concordance of Genomic Alterations Between Primary and Recurrent Breast Cancer. Molecular Cancer Therapeutics (March 7, 2014).
  6. Thomas RK, et al. High-throughput oncogene mutation profiling in human cancer. Nat Gen 39 (3): 347-351. (2007).
  7. Chen-Hsiang Yeang, et al. Combinatorial patterns of somatic gene mutations in cancer. The FASEB Journal 22: 2605-2622. (2008).
  8. Pao W. The VICC Personalized Cancer Medicine Initiative. Review Symposium. Vanderbilt-Ingram Cancer Center 8th Annual Oncology & Hematology. (2011).
  9. MacConaill, L.E et al. Clinical Implications of the Cancer Genome. Journal of Clinical Oncology 28 (35): 5219 – 5228. (2010).
  10. Corless C. Semiconductor-based Sequencing for Cancer Diagnostics: Gamblig with Chips. Association of Molecular Pathology annual meeting 2011. [online] Click here
  11. Li M. Next Generation Cancer Gene Sequencing for Clinically Actionable Mutations. Association of Molecular Pathology annual meeting 2011. [online] Click here
  12. Li M. The Efficacy of Next Generation Sequencing for Detection of Clinically Actionable Mutations in Cancer. Advances in Genome Biology and Technology 2012. [online] Click here
  13. Stratton, MR, et al. The cancer genome. Nature 458 (7239): 719. (2009).
  14. MacConaill, L.E et al. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. Plos One 4 (11): e7887 (2009).
  15. La Thangue, N. B. et al. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587–596 (2011)
  16. Wong, K.M., et al. Unraveling the genetics of cancer: Genome Sequencing and Beyond. Annu. Rev. Genomics Hum. Genet. 12: 407-30 (2011)
  17. National Cancer Institute. Targeted Cancer Therapies [online] Click here (2012).
  18. Jackson D. et al. Personalized cancer medicine—advances and socio-economic challenges. Nature Reviews Clinical Oncology 8, 735-741(2011).
  19. Ross, J.S. et al. Whole cancer genome sequencing by Next-Generation Methods. Am. J. Clin. Pathol. 136: 527-539 (2011).
  20. Leary R.J. et al. Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing. Sci Transl Med. 2 (20): 20ra14. (2010).
  21. Strausberg R.L. et al. Whole-genome cancer analysis as an approach to deeper understanding of tumor biology. British Journal of Cancer 102: 243-248 (2010).
  22. Taylor B.S. et al. Clinical cancer genomics: how soon is now? J Pathol 223: 318-326 (2011).
  23. Vogenberg F.R. et al. Personalized Medicine. Part I: Evolution and Development into Theranostics. P&T 35 (10). (2010).
  24. McDermott U. et al. High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods Enzymol.438:331-41. (2008)
  25. Shen Yang, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood, American Society of Hematology 118 (20): 5593-5603. (2011).
  26. McDermott U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 104(50):19936-41. (2007).
  27. Jänne PA. et al. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 8(9):709-23. Review. (2009).
  28. J. van ’t Veer L, et al. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452 (3): 564-570. (2008).
  29. Dias-Santagata, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Molecular Medicine 2 (5): 146–158. (2010).
  30. The International Cancer Genome Consortium. International network of cancer genome projects. Nature 464 (7291): 993–998. (2010).
  31. Barretina J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-307. (2012).
  32. Mathew J. et. al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575. (2012)
  33. Nystrom JS. et al. Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: Impact on diagnosis, treatment, and survival. Oncotarget, Advance Publications. (2012).
  34. Dumur CI. et al. Clinical Verification of the performance of the Pathwork Tissue of Origin Test. Am J Clin Pathol;136:924-933. (2011).
  35. Laouri M. et al. Potential Clinical Utility of Gene-Expression profiling in Identifying tumors of uncertain origin. Personalized Medicine, 8 (6), 615-622. (2011).
  36. Takei H. et al. Gene-Expression assays and personalized cancer care: Tissue of Origin for Cancer of Unknown primary origin. Personalized Medicine 8(4), 429–436. (2011).
  37. Hornberger J. et al. Cost- effectiveness of gene-expression profiling for tumor-site origin. AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine, San Diego, CA. (2012).
  38. Pollen M. et al. Utility of gene-expression profiling for reporting difficutl to diagnose cancers. , G Wellman, M Lowery-Nordberg. Association for Molecular Pathologists Annual Meeting, November 17-19, Grapevine, TX. (2011).
  39. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 7403 (2012).
  40. Alexandrov, LB. et al. Signatures of mutational processes in human cancer. Nature 500(7463): 415-21 (2013).